Scotland approves tebentafusp for metastatic uveal melanoma, a rare eye cancer with a median survival of around 12 months.
Medscape News UK
Source link : https://www.medscape.com/viewarticle/smc-accepts-first-drug-improve-survival-uveal-melanoma-2026a1000npg?src=rss
Author :
Publish date : 2026-07-14 10:21:00
Copyright for syndicated content belongs to the linked Source.